Company / EPS (Diluted)
Tandem Diabetes Care EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$3.43
FY2025
5-year range
-$3.43 / $0.24
FY2021-FY2025
Trend
-133.3%
vs FY2024
Sector context
#141 of 159
Health Care
What the data says
Tandem Diabetes Care's eps (diluted) of $-3.43 is lower than 89% of companies in the Health Care sector (FY2025). EPS (Diluted) has fluctuated over the past 10 years, ranging from $-25.04 in FY2017 to $0.24 in FY2023.
Based on SEC 10-K filings.
-3.43 in FY2025.
Declined from $0.24 to $-3.43 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 159This company -$3.43 Sector average $1.56
▼
-320.3% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 133.3% year-over-year.
- Ranks #141 out of 159 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2023.
- Lowest eps (diluted) in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.43 | -133.3% |
| FY2024 | -$1.47 | -712.5% |
| FY2023 | $0.24 | +142.9% |
| FY2022 | -$0.56 | -33.3% |
| FY2021 | -$0.42 | +6.7% |
| FY2020 | -$0.45 | -12.5% |
| FY2019 | -$0.40 | +78.0% |
| FY2018 | -$1.82 | +92.7% |
| FY2017 | -$25.04 | -632.2% |
| FY2016 | -$3.42 | +84.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026